Clinical Trials · NCT04427787
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Enrollment
- 69
- Start date
- Jun 2020
- Locations
- 1 site, Italy
- Primary endpoint
- Objective Response Rate (ORR)